Barkley PMHNP
PsycHoPHarMacology Practice
QuestioNs V2.0 coMPreHeNsiVe 150-
QuestioN exaMiNatioN BaNk for
PsycHiatric-MeNtal HealtH Nurse
PractitioNer certificatioN a well
detailed oNe writteN aNd
graded a+ uPgraded
Instructions
This examination consists of 150 multiple-choice questions designed to assess advanced
knowledge in psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner
(PMHNP). Questions range from foundational concepts to complex clinical application scenarios.
Select the single best answer for each question. Each question is followed by a detailed
rationale explaining the correct answer and why the distractors are incorrect.
Section 1: Neurobiology and Receptor Pharmacology (Questions 1-15)
,Question 1
The PMHNP is reviewing the role of second messenger systems in psychopharmacology. Which
statement accurately describes the function of cyclic adenosine monophosphate (cAMP) in
neuronal signaling?
A) cAMP directly activates neurotransmitter receptors
B) cAMP serves as a second messenger that amplifies intracellular signaling cascades
C) cAMP is responsible for neurotransmitter reuptake
D) cAMP is only involved in dopamine metabolism
Correct Answer: B
Rationale: cAMP is a critical second messenger that amplifies signals from G-protein coupled
receptors, activating protein kinase A and downstream signaling pathways. Option A is incorrect
as cAMP does not directly activate receptors. Option C is incorrect as reuptake involves
transporters. Option D is incorrect as cAMP is involved in multiple neurotransmitter systems.
Question 2
A patient with treatment-resistant depression is being considered for a medication that targets
the mTOR signaling pathway. This pathway is important because it:
A) Inhibits serotonin synthesis
B) Promotes synaptic protein synthesis and neuroplasticity
C) Blocks dopamine reuptake
D) Enhances GABA degradation
Correct Answer: B
Rationale: The mTOR signaling pathway promotes synaptic protein synthesis and
neuroplasticity, which is a key mechanism for rapid-acting antidepressants like ketamine. Option
A is incorrect as mTOR does not inhibit serotonin synthesis. Option C describes stimulant
mechanisms. Option D is incorrect.
Question 3
The PMHNP is explaining to a student that certain psychotropic medications have "off-target"
effects. Which statement best describes off-target effects?
A) Effects that occur only in the target organ
B) Effects mediated by receptors other than the primary therapeutic target
,C) Effects that are always beneficial
D) Effects that occur only at toxic doses
Correct Answer: B
Rationale: Off-target effects are mediated by receptors other than the primary therapeutic
target, often contributing to side effect profiles. Option A is incorrect. Option C is incorrect as
off-target effects may be adverse. Option D is incorrect as they can occur at therapeutic doses.
Question 4
A patient is started on a medication that acts as a positive allosteric modulator at the GABA-A
receptor. This medication's mechanism of action:
A) Directly activates the receptor
B) Enhances the effect of GABA without directly activating the receptor
C) Blocks the receptor completely
D) Degrades GABA in the synaptic cleft
Correct Answer: B
Rationale: Positive allosteric modulators enhance the effect of the endogenous ligand (GABA)
without directly activating the receptor. Option A describes direct agonists. Option C describes
antagonists. Option D describes enzymatic degradation.
Question 5
Which neurotransmitter system is most directly involved in the pathophysiology of obsessive-
compulsive disorder and is the primary target of first-line pharmacotherapy?
A) Dopamine
B) Serotonin
C) Norepinephrine
D) Glutamate
Correct Answer: B
Rationale: The serotonin system is primarily implicated in OCD pathophysiology, and SSRIs are
first-line pharmacotherapy. Dopamine (A), norepinephrine (C), and glutamate (D) are involved
but not the primary targets.
, Question 6
The PMHNP is considering a medication that acts as an agonist at the 5-HT1A receptor. This
receptor is most directly associated with:
A) Antipsychotic effects
B) Anxiolytic and antidepressant effects
C) Weight gain
D) Sedation
Correct Answer: B
Rationale: 5-HT1A receptor agonism is associated with anxiolytic and antidepressant effects.
Buspirone is a 5-HT1A partial agonist. Antipsychotic effects (A) involve D2 and 5-HT2A receptors.
Weight gain (C) involves H1 and 5-HT2C receptors. Sedation (D) involves H1 receptors.
Question 7
A patient with schizophrenia has persistent negative symptoms despite adequate antipsychotic
treatment. The PMHNP considers a medication that acts on the glutamatergic system. Which
mechanism is most promising for negative symptoms?
A) NMDA receptor antagonism
B) NMDA receptor agonism at the glycine site
C) AMPA receptor antagonism
D) GABA-A receptor modulation
Correct Answer: B
Rationale: NMDA receptor agonism at the glycine site (via glycine or D-serine) may improve
negative symptoms. NMDA receptor antagonism (A) is associated with psychosis. AMPA
receptor antagonism (C) is not the primary strategy. GABA-A modulation (D) is more relevant to
anxiety.
Question 8
The PMHNP is reviewing the role of the endocannabinoid system in psychiatric disorders. Which
statement about the endocannabinoid system is accurate?
A) It has no role in psychiatric illness
B) It modulates neurotransmitter release and stress responses
C) It is exclusively involved in appetite regulation
D) It is only activated by exogenous cannabinoids
PsycHoPHarMacology Practice
QuestioNs V2.0 coMPreHeNsiVe 150-
QuestioN exaMiNatioN BaNk for
PsycHiatric-MeNtal HealtH Nurse
PractitioNer certificatioN a well
detailed oNe writteN aNd
graded a+ uPgraded
Instructions
This examination consists of 150 multiple-choice questions designed to assess advanced
knowledge in psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner
(PMHNP). Questions range from foundational concepts to complex clinical application scenarios.
Select the single best answer for each question. Each question is followed by a detailed
rationale explaining the correct answer and why the distractors are incorrect.
Section 1: Neurobiology and Receptor Pharmacology (Questions 1-15)
,Question 1
The PMHNP is reviewing the role of second messenger systems in psychopharmacology. Which
statement accurately describes the function of cyclic adenosine monophosphate (cAMP) in
neuronal signaling?
A) cAMP directly activates neurotransmitter receptors
B) cAMP serves as a second messenger that amplifies intracellular signaling cascades
C) cAMP is responsible for neurotransmitter reuptake
D) cAMP is only involved in dopamine metabolism
Correct Answer: B
Rationale: cAMP is a critical second messenger that amplifies signals from G-protein coupled
receptors, activating protein kinase A and downstream signaling pathways. Option A is incorrect
as cAMP does not directly activate receptors. Option C is incorrect as reuptake involves
transporters. Option D is incorrect as cAMP is involved in multiple neurotransmitter systems.
Question 2
A patient with treatment-resistant depression is being considered for a medication that targets
the mTOR signaling pathway. This pathway is important because it:
A) Inhibits serotonin synthesis
B) Promotes synaptic protein synthesis and neuroplasticity
C) Blocks dopamine reuptake
D) Enhances GABA degradation
Correct Answer: B
Rationale: The mTOR signaling pathway promotes synaptic protein synthesis and
neuroplasticity, which is a key mechanism for rapid-acting antidepressants like ketamine. Option
A is incorrect as mTOR does not inhibit serotonin synthesis. Option C describes stimulant
mechanisms. Option D is incorrect.
Question 3
The PMHNP is explaining to a student that certain psychotropic medications have "off-target"
effects. Which statement best describes off-target effects?
A) Effects that occur only in the target organ
B) Effects mediated by receptors other than the primary therapeutic target
,C) Effects that are always beneficial
D) Effects that occur only at toxic doses
Correct Answer: B
Rationale: Off-target effects are mediated by receptors other than the primary therapeutic
target, often contributing to side effect profiles. Option A is incorrect. Option C is incorrect as
off-target effects may be adverse. Option D is incorrect as they can occur at therapeutic doses.
Question 4
A patient is started on a medication that acts as a positive allosteric modulator at the GABA-A
receptor. This medication's mechanism of action:
A) Directly activates the receptor
B) Enhances the effect of GABA without directly activating the receptor
C) Blocks the receptor completely
D) Degrades GABA in the synaptic cleft
Correct Answer: B
Rationale: Positive allosteric modulators enhance the effect of the endogenous ligand (GABA)
without directly activating the receptor. Option A describes direct agonists. Option C describes
antagonists. Option D describes enzymatic degradation.
Question 5
Which neurotransmitter system is most directly involved in the pathophysiology of obsessive-
compulsive disorder and is the primary target of first-line pharmacotherapy?
A) Dopamine
B) Serotonin
C) Norepinephrine
D) Glutamate
Correct Answer: B
Rationale: The serotonin system is primarily implicated in OCD pathophysiology, and SSRIs are
first-line pharmacotherapy. Dopamine (A), norepinephrine (C), and glutamate (D) are involved
but not the primary targets.
, Question 6
The PMHNP is considering a medication that acts as an agonist at the 5-HT1A receptor. This
receptor is most directly associated with:
A) Antipsychotic effects
B) Anxiolytic and antidepressant effects
C) Weight gain
D) Sedation
Correct Answer: B
Rationale: 5-HT1A receptor agonism is associated with anxiolytic and antidepressant effects.
Buspirone is a 5-HT1A partial agonist. Antipsychotic effects (A) involve D2 and 5-HT2A receptors.
Weight gain (C) involves H1 and 5-HT2C receptors. Sedation (D) involves H1 receptors.
Question 7
A patient with schizophrenia has persistent negative symptoms despite adequate antipsychotic
treatment. The PMHNP considers a medication that acts on the glutamatergic system. Which
mechanism is most promising for negative symptoms?
A) NMDA receptor antagonism
B) NMDA receptor agonism at the glycine site
C) AMPA receptor antagonism
D) GABA-A receptor modulation
Correct Answer: B
Rationale: NMDA receptor agonism at the glycine site (via glycine or D-serine) may improve
negative symptoms. NMDA receptor antagonism (A) is associated with psychosis. AMPA
receptor antagonism (C) is not the primary strategy. GABA-A modulation (D) is more relevant to
anxiety.
Question 8
The PMHNP is reviewing the role of the endocannabinoid system in psychiatric disorders. Which
statement about the endocannabinoid system is accurate?
A) It has no role in psychiatric illness
B) It modulates neurotransmitter release and stress responses
C) It is exclusively involved in appetite regulation
D) It is only activated by exogenous cannabinoids
